A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period

Trial Profile

A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Omiganan (Primary)
  • Indications Rosacea
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Cutanea Life Sciences
  • Most Recent Events

    • 24 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Aug 2017.
    • 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top